Table 1. Clinical and pathological manifestations of enrolled IgAN patients.
| Characteristics | Mean ± SD (IQR or percentage) | ||
| Discovery cohort | Replication cohort | combined cohort | |
| Age (year) | 32.94±9.96 | 32.62±10.25 | 32.77±10.09 |
| Gender (male) | 65/96 (67.71%) | 67/109 (61.47%) | 132/205 (64.39%) |
| Hypertension (%) | |||
| with hypertension | 45/96 (46.87%) | 52/109 (47.71%) | 97/205 (47.32%) |
| without hypertension | 51/96 (53.13%) | 57/109 (52.29%) | 108/205 (52.68%) |
| Initial proteinuria (g/day, median, IQR) | 1.59 (0.93, 3.22) | 1.26 (0.79,2.47) | 1.40 (0.84,2.76) |
| <1 (%) | 26/96 (27.08%) | 42/109 (38.53%) | 70/205 (34.15%) |
| 1–3.5 (%) | 48/96 (50%) | 54/109 (49.54%) | 102/205 (49.76%) |
| ≥3.5 (%) | 22/96 (22.92%) | 13/109 (11.93%) | 33/205 (16.09%) |
| eGFR (ml/min per 1.73 m2) | 77.27±37.26 | 86.44±39.58 | 82.15±38.65 |
| Oxford classification (%) | |||
| M score | |||
| M0 | 16/96 (16.67%) | 18/109 (16.51%) | 34/205 (16.59%) |
| M1 | 80/96 (83.33%) | 91/109 (83.49%) | 171/205 (83.41%) |
| E score | |||
| E0 | 72/96 (75%) | 90/109 (82.57%) | 162/205 (79.02%) |
| E1 | 24/96 (25%) | 19/109 (17.43%) | 43/205 (20.98%) |
| S score | |||
| S0 | 62/96 (64.58%) | 52/109 (47.71%) | 114/205 (55.61%) |
| S1 | 34/96 (35.42%) | 57/109 (52.29%) | 91/205 (44.39%) |
| T score | |||
| T0 | 63/96 (65.63%) | 31/109 (28.44%) | 94/205 (45.85%) |
| T1 | 15/96 (15.62%) | 59/109 (54.13%) | 74/205 (36.10%) |
| T2 | 18/96 (18.75%) | 19/109 (17.43%) | 37/205 (18.05%) |